Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab, Plinabulin, and Docetaxel in Previously Treated Metastatic NSCLC
NCT05599789Phase 2Active, not recruiting
- Sponsor
- Peking Union Medical College Hospital
- Start
- Feb 2023
- Primary completion
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pembrolizumab and plinabulin in non-small cell lung cancer (NSCLC), sponsored by Peking Union Medical College Hospital. Primary endpoint: Objective Response Rate at 1 year. Started Feb 2023; status: active, not recruiting.
02
Drugs
pembrolizumabplinabulin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05599789.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05599789.